133 related articles for article (PubMed ID: 19698927)
1. The impact of gene profiling in chronic myeloid leukaemia.
Yong AS; Melo JV
Best Pract Res Clin Haematol; 2009 Jun; 22(2):181-90. PubMed ID: 19698927
[TBL] [Abstract][Full Text] [Related]
2. Role of gene-expression profiling in chronic myeloid leukemia.
Schmidt S; Wolf D
Expert Rev Hematol; 2009 Feb; 2(1):93-103. PubMed ID: 21082998
[TBL] [Abstract][Full Text] [Related]
3. Meta-analysis of microarray data: The case of imatinib resistance in chronic myelogenous leukemia.
Burguillo FJ; Martin J; Barrera I; Bardsley WG
Comput Biol Chem; 2010 Jun; 34(3):184-92. PubMed ID: 20619742
[TBL] [Abstract][Full Text] [Related]
4. New targets for Ph+ leukaemia therapy.
Martinelli G; Iacobucci I; Papayannidis C; Soverini S
Best Pract Res Clin Haematol; 2009 Sep; 22(3):445-54. PubMed ID: 19959093
[TBL] [Abstract][Full Text] [Related]
5. Chronic myelogenous leukemia with the e6a2 BCR-ABL and lacking imatinib response: presentation of two cases.
Vefring HK; Gruber FX; Wee L; Hovland R; Hjorth-Hansen H; Gedde Dahl T; Meyer P
Acta Haematol; 2009; 122(1):11-6. PubMed ID: 19641300
[TBL] [Abstract][Full Text] [Related]
6. Imatinib resistance and progression of CML to blast crisis: somatic hypermutation AIDing the way.
Strout MP; Schatz DG
Cancer Cell; 2009 Sep; 16(3):174-6. PubMed ID: 19732715
[TBL] [Abstract][Full Text] [Related]
7. Down-regulation of hsa-miR-10a in chronic myeloid leukemia CD34+ cells increases USF2-mediated cell growth.
Agirre X; Jiménez-Velasco A; San José-Enériz E; Garate L; Bandrés E; Cordeu L; Aparicio O; Saez B; Navarro G; Vilas-Zornoza A; Pérez-Roger I; García-Foncillas J; Torres A; Heiniger A; Calasanz MJ; Fortes P; Román-Gómez J; Prósper F
Mol Cancer Res; 2008 Dec; 6(12):1830-40. PubMed ID: 19074828
[TBL] [Abstract][Full Text] [Related]
8. [Circumventing resistance to imatinib therapy in chronic myeloid leukemia].
Minami Y; Naoe T
Gan To Kagaku Ryoho; 2009 Apr; 36(4):544-7. PubMed ID: 19381024
[TBL] [Abstract][Full Text] [Related]
9. [Chronic myeloid leukemia in the 21st century: biology and treatment].
Chávez-González MA; Ayala-Sánchez M; Mayani H
Rev Invest Clin; 2009; 61(3):221-32. PubMed ID: 19736811
[TBL] [Abstract][Full Text] [Related]
10. Effects of imatinib mesylate on normal bone marrow cells from chronic myeloid leukemia patients in complete cytogenetic response.
Sanchez-Guijo FM; Hernandez JM; Lumbreras E; Morais P; Santamaría C; Garcia JL; Gutierrez NC; Miguel JF; Del Cañizo MC
Leuk Res; 2009 Jan; 33(1):170-3. PubMed ID: 18722011
[TBL] [Abstract][Full Text] [Related]
11. Comparative proteome profiling and functional analysis of chronic myelogenous leukemia cell lines.
Fontana S; Alessandro R; Barranca M; Giordano M; Corrado C; Zanella-Cleon I; Becchi M; Kohn EC; De Leo G
J Proteome Res; 2007 Nov; 6(11):4330-42. PubMed ID: 17935311
[TBL] [Abstract][Full Text] [Related]
12. Update: chronic myelogenous leukemia clinical practice guidelines.
O'Brien SM; Kantarjian H; Radich J
J Natl Compr Canc Netw; 2003 Jan; 1 Suppl 1():S29-40. PubMed ID: 19795574
[TBL] [Abstract][Full Text] [Related]
13. Imatinib: a second look. Longer follow-up in chronic myeloid leukaemia: clear advantages.
Prescrire Int; 2008 Dec; 17(98):226-8. PubMed ID: 19415889
[TBL] [Abstract][Full Text] [Related]
14. BCR-ABL1-induced expression of HSPA8 promotes cell survival in chronic myeloid leukaemia.
José-Enériz ES; Román-Gómez J; Cordeu L; Ballestar E; Gárate L; Andreu EJ; Isidro I; Guruceaga E; Jiménez-Velasco A; Heiniger A; Torres A; Calasanz MJ; Esteller M; Gutiérrez NC; Rubio A; Pérez-Roger I; Agirre X; Prósper F
Br J Haematol; 2008 Aug; 142(4):571-82. PubMed ID: 18537972
[TBL] [Abstract][Full Text] [Related]
15. Telomeres and telomerase in chronic myeloid leukaemia: impact for pathogenesis, disease progression and targeted therapy.
Keller G; Brassat U; Braig M; Heim D; Wege H; Brümmendorf TH
Hematol Oncol; 2009 Sep; 27(3):123-9. PubMed ID: 19569255
[TBL] [Abstract][Full Text] [Related]
16. [Minimal residual disease in malignant diseases of the blood II. Translation and therapeutic consequences].
Hokland P; Ommen HB; Nyvold CG; Stentoft J; Braendstrup K; Andersen BL; Mikkelsen LS; Ostergaard M
Ugeskr Laeger; 2009 Jan; 171(4):232-5. PubMed ID: 19174038
[TBL] [Abstract][Full Text] [Related]
17. The metabolic consequences of imatinib mesylate: Changes on glucose, lypidic and bone metabolism.
Breccia M; Alimena G
Leuk Res; 2009 Jul; 33(7):871-5. PubMed ID: 19307018
[TBL] [Abstract][Full Text] [Related]
18. Interferon-alpha may restore sensitivity to tyrosine-kinase inhibitors in Philadelphia chromosome positive acute lymphoblastic leukaemia with F317L mutation.
Potenza L; Volzone F; Riva G; Soverini S; Martinelli S; Iacobucci I; Gnani A; Barozzi P; Forghieri F; Morselli M; Zanetti E; Maccaferri M; Baccarani M; Martinelli G; Torelli G; Luppi M
Br J Haematol; 2009 Jul; 146(2):227-30. PubMed ID: 19545285
[No Abstract] [Full Text] [Related]
19. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
[TBL] [Abstract][Full Text] [Related]
20. Gene expression analysis identifies a genetic signature potentially associated with response to alpha-IFN in chronic phase CML patients.
Hagberg A; Olsson-Strömberg U; Wickenberg-Bolin U; Göransson H; Isaksson A; Bengtsson M; Höglund M; Simonsson B; Barbany G
Leuk Res; 2007 Jul; 31(7):931-8. PubMed ID: 17207527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
